Clinical Efficacy and Survival Analysis of Dacomitinib Combined with Cetuximab in the Treatment of Advanced Non-small Cell Lung Cancer
[Objective]To investigate the clinical efficacy and survival of dacomitinib combined with cetuximab in the treatment of advanced non-small cell lung cancer(NSCLC).[Methods]A total of 204 patients with advanced NSCLC were randomly divided into the control group and the observation group,with 102 cases in each group.The control group was given cetuximab treatment,and the observation group was given dacomitinib orally in addition to cetuximab.In both groups,medication continued until disease progression or toxic intolerance.The anti-tumor efficacy,tumor marker chan-ges,lung function and adverse drug reactions of the two groups were compared after 3 courses of continuous treatment,and the 1-year survival was also analyzed between the two groups.[Results]In the observation group,3 patients dropped off due to incomplete treatment,and 5 cases dropped off in the control group.Finally,99 cases in the observation group and 97 cases in the control group were included,respectively.The clinical control rate of the observation group was higher than that of the control group(P＜0.05).The levels of tumor-specific growth factor(TSGF),cell proliferation antigen(PCNA),carcinoembryonic antigen(CEA)after treatment were lower than those before treatment.And the levels of TSGF,PCNA and CEA in the observation group after treatment were lower than those in the control group(P＜0.05).The forced vital capacity(FVC)and forced expiratory volume in the first second(FEV1)/FVC in the two groups after treatment were higher than those before treatment(P＜0.05),while those in the observation group were higher after treatment(P＜0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups(P＞0.05).By the end of follow-up,2 cases in the control group and 1 case in the observation group were lost to follow-up.From the 1-year survival survey,62 of 98 patients survived in the observation group and 47 of 95 patients sur-vived in the control group.The 1-year overall survival curve of the observation group was better than that of the control group(P＜0.05).[Conclusion]Dacomitinib combined with Cetuximab in the treatment of advanced NSCLC can enhance anti-tumor efficacy,reduce tumor marker levels,and improve short-term survival.
万方数据
维普
